The Value of Pharmacogenomic Information

This paper studies of couple evidence from a real-world implementation of pharmacogenomic testing with a discrete event simulation model. It uses the framework to evaluate the cost-effectiveness of various genetic testing strategies. The paper finds that the cost-effectiveness of multiplexed genetic testing (e.g., whole genome sequencing) hinges on the ability of a health system to ensure that dense genotypic information is routinely utilized by physicians. Moreover, while much attention has been paid to lowering the cost of genetic tests, we demonstrate that in practice, other scientific and behavioral factors, focused on certain highyield drug-gene pairs, are key to implementing precision medicine in ways that maximize its value.